

Alternatives to the statistical mass confusion of testing for “no effect”

Josh L. Morgan

Washington University in St. Louis, Department of Ophthalmology and Visual Sciences,
Neuroscience, Biology and Biomedical Science.

jlmorgan@wustl.edu

ABSTRACT

Cell biology has agreed to test the null-hypothesis that there was exactly zero experimental effect. This hypothesis is a-priori-impossible. Testing this impossible hypothesis has led to a cell biology literature that is largely indifferent to effect size. The first part of the solution is to limit statistical hypothesis testing to the small subset of experiments where a meaningful effect size can be defined prior to the experiment. The second part of the solution is to make confidence intervals the default statistic in cell biology.

MAIN TEXT

Biologists collect measurements that can be used to inspire, refine, or distinguish between models of the world. Statistical models help us determine how much our limited sample sizes can tell us about the likely distributions of these measures in the full population. Accurately reporting our measurements, therefore, means transparently reporting two classes of information: *magnitude* (mean, median, correlation coefficient, etc.) and *uncertainty* (standard error, confidence interval).

Statistical analysis can also provide a third class of information, the frequency that an experiment would produce the observed results if a given hypothesis were true (p-value). When rigorously performed, null hypothesis significance testing (NHST) is a powerful tool for making decisions about data^{1 2}. Problems with the interpretation of NHST^{1,3-9} have plagued it since it was popularized by Fisher almost a hundred years ago. These misinterpretations range from subtle philosophical points about the meaning of probability to gross logical errors such as claiming large p-values as evidence that the null hypothesis is true. However, there is one NHST convention that biologists adopted that is so damaging that its acceptance has caused a crisis in biological thinking.

The convention is to automatically define the null hypothesis being tested as the hypothesis that there was no effect¹⁰. In Jacob Cohen's words, the null hypothesis became the nil hypothesis¹¹. Most commonly, the no-effect hypothesis is the proposition that the difference between the mean of a control group and the mean of an experimental group is zero. There is nothing in the conceptual framework of NHST that says the effect size being tested must be zero. A biologist could decide that, given common errors in measurement and the types of effect they are interested in, they test to see if the experimental group mean is at least 20% larger than the control group mean. But rather than factoring in potential sources of error and biologically relevant minimum effect sizes, the much easier question is asked: *effect* or *no-effect*.

Defining the null hypothesis as the no-effect hypothesis makes some sense as an entry point in screening for experimental effects. If many experiments are being performed and potential effect sizes are uncharacterized, then NHST for no effect can alert a researcher to an experiment that should be followed up on. The problem is that these tests have also become the endpoint of quantification for much of cell biology. An asterisk over the bar graph is the gold standard for supporting a biological claim. Testing for no-effect is, in no way, up to this task.

It may seem reasonable to ask whether an experimental treatment had an effect, but there is a difference between the hallway definition of “no-effect” and the statistical definition of “no-effect”. Imagine you stop to talk to a colleague and ask if the blood pressure drug they were testing had an effect. Their experience will tell them that a reduction in blood pressure from 150 mmHg to 149.9 mmHg is not clinically relevant while a reduction to 125 mmHg could be life saving. If they excitedly tell you that the drug had an effect, you can assume the reduction wasn’t by 0.1 mmHg. The same isn’t true of a t-test. If you ask the t-test if the difference was zero, the p-value only tells you how often the observed difference in means would be observed if the true effect size was *exactly* zero.

We can reject the no-effect null hypothesis without doing an experiment.

Rejecting the no-effect hypothesis tells us about the experiment, not the biology. First, in a highly interconnected network like a living organism, the proposition that one component is perfectly independent of another component is trivially false. By virtue of being part of the same organism, all molecular pathways and cells can be assumed to be either directly or indirectly connected. Detecting the connection might require extremely sensitive equipment and many samples, but the question is never “Is there a connection?” The meaningful question is always “How strong is the connection?”

The second problem with the no-effect hypothesis is that all experiments can be assumed to have some non-zero sampling bias ¹². For instance, it is now recognized that circadian rhythms have detectable effects on most cellular processes. How much of the published biological literature has strong controls for time of day? The imperfections in experiments don’t have to be large to undermine the no-effect hypothesis. They only need to be imperfect.

Finally, the statistical models underpinning NHST are mathematical simplifications of biological processes and sampling procedures that are full of unknown variables. There should be no expectation that these models can perfectly predict the distribution of results that would occur if there was no experimental effect. What, then, does it mean if the observed results don’t perfectly fit a modeled no-effect distribution? The problem is not with comparing data to statistical models. Asking how much bigger an observed effect size is than the range of what would be predicted from a given model is a great way to make sense of an experimental effect. The problem is with treating *all* detectable deviations from a modeled result as biologically meaningful.

The upshot of these three sources of guaranteed experimental effects is that p-values for ALL no-effect tests will become infinitesimally small as sample sizes approach infinity. Imagine you have a dial that increases the sample size in all publications. As you turn the dial up, asterisks begin appearing over every plot and bar graph. You can keep turning the knob until each bar has a string of asterisks that runs off the page and the conclusion of every test is that the result was extremely statistically significant. The biology hasn’t changed. The questions haven’t changed. But increasing the sample size has guaranteed the same answer to every question.

No-effect testing is imploding.

Why does no-effect testing kind of work sometimes? As discussed above, testing for no-effect can be a useful screening tool. Testing for no-effect can also be a crude rule-of-thumb for effect size. If the sample sizes are small and measures are noisy, then a small p-value means there was probably a big effect. But what happens to no-effect testing when automation allows massive datasets to be analyzed with minimal human supervision?

Large sample sizes: Large sample sizes cause trivial effects to drive p-values below threshold.

Low prior probability: Automation makes it possible to test thousands of possible factors (genes, cells, conditions) that each have a low probability of being important for the phenomena of interest. If the criteria for follow up is rejection of the no-effect hypothesis, researchers can be expected to follow a drunkard's walk¹³ from one trivial true-positive to the next.

Meaningless measures: Data analysis software makes it easy to generate many different highly derived measures from the same data. Interpreting the result in terms of effect or no-effect makes it easy to claim that a manipulation had a significant effect even when there is no clear biological interpretation of the measure.

The solution starts and ends with considering effect sizes.

Effect size should be at the center of planning, analyzing, and discussing cell biology experiments. Before a measurement is performed it should be clear to the researcher what different values of the measurement might say about the biology. Before results are discussed, it should be clear to the reader or audience what different values of the measurement might say about the biology.

Imagine we have a mutant mouse model of a mitochondrial disease in which the number of mitochondria in each cell is reduced to half the normal amount. We want to use this mouse model to test the efficacy of a drug treatment. The data we collect is the number of mitochondria, but we don't necessarily care whether a cell has 20 or 21 mitochondria. We care how much a treatment moves mitochondria number along a scale defined by mutant mitochondria number at one end and healthy mitochondria number at the other end ($\% \text{recovery} = [\text{treatment-mutant}] / [\text{healthy} - \text{mutant}] * 100$, Figure 1A). Defining a measure for percent recovery does not impact the mathematics of the quantification yet it is critical to ability to interpret and discuss the data.







Figure 1: Comparison of hypothetical population distributions with different ways to represent results. Mitochondria number per cell is measured in healthy mice, a mutant mouse disease model, and in disease model mice that have undergone a treatment. Three possible results are shown for the treatment. A) Hidden population distributions of mitochondria number healthy (blue), disease model (red), and treatment (grey). B) All treatment results are statistically significant when the no-effect hypothesis is tested. C) Only result C is statistically significant when the null hypothesis of 20% or less recovery is tested. D) Reporting effect size in the absence of a quantitative hypothesis. Comparison in of groups indicate 95% confidence interval.

Let's first consider the worst way to deal with the data. After performing the experiment, we perform a standard t-test for no-effect. In this case, very different biological effects can produce the same conclusion. Analysis of reliably small effects, variable effects, and reliable strong effects can all reject the null hypothesis of no-effect (Figure 1AB). Performing a one-tailed test (difference is ≤ 0) doesn't resolve this issue. The bar graphs (Figure 1B) reflect the view that the important information provided by the experiment is whether the treatment had a statistical effect. To determine if the treatment effect is biologically meaningful, the reader will have to decode the y axis of the plot, compare it to the standard error bars, then look up the sample size, and then read the text to try to determine what an important effect size might be.

At the other extreme, let's imagine that we perform all the steps required for rigorous NHST. The hypothesis we are testing is that the treatment is ineffective. Before performing the experiment, we consider of the efficacy of alternative treatments, how variation in mitochondria number relates to cell health, and the magnitude of potential sources of experimental bias. Based on previous descriptive studies, we propose a quantitative null hypothesis, that the treatment will result in less than 20% recovery of mitochondria number. We then define a p-value threshold ($p < 0.01$) that reflects the relative costs of following up on a false positive result or neglecting to follow up on a false negative¹⁴. We perform a power analysis to ensure that our sample size would be large enough to reliably detect the effect size of interest. We then preregister the experiment with an online database to reduce the impact of publication bias on the rate of false positives in the field. We then perform the experiment and calculate a p-value. Given the totality of data and experimental design, this p-value gives us a quantitative and rational basis for making decisions. To report the results, we use scatter plots that show both the raw mitochondria counts (Figure 1C, y-axis) and our criteria for meaningful recovery (dashed lines). It is now clear to the reader what we consider an important effect size and how the data is distributed relative to that effect size.

Now let's imagine that we understand the limits of testing for no effect, but we also don't know enough about the meaning of potential effect sizes or about sources of variance to design a rigorous NHST. This state of uncertainty about meaningful effect sizes is the norm for cell biology experiments. Critically, the alternative to rigorous NHST is not to perform a bad NHST. The alternative is to rigorously characterize the effect size. We, therefore, calculate a confidence interval for the difference between the untreated mutant group and

the treated mutant group (Figure 1D). When expressed in the form of percent recovery, the confidence interval provides biologically meaningful information about whether the treated group looks more like the disease model mice or more like healthy mice. The range of the interval distinguishes between robust and unreliable results. Even if all the information was available to perform a rigorous NHST, it is the confidence interval and not the p-value, that would provide useful information for understanding the biology and comparing experiments.

The confidence interval should be biology's default statistic.

Confidence intervals are an efficient and transparent way to represent both magnitude and uncertainty. As such, confidence intervals are the most commonly proposed alternative to p-values^{11,15,16}. Critically, confidence intervals can function as the core statistic in exploratory studies, rigorously descriptive studies, and in NHST.

A confidence interval is the range of values that the data, combined with a statistical model, predicts will include the real value of the population. If the statistical model is working well and is applied to an infinite number of experiments, a 95% confidence interval will fail to include the real population value 5% of the time. Confidence intervals can be represented in text as "1% to 6% (CI95)" or as the APA recommended notation "CI95[1%,6%]". The magnitude reported in the confidence interval can be any continuous statistic such as mean, difference in means, regression coefficient, or Cohen's d. The size of the interval is determined by comparing sample size to a model of the variance of the measure. In general, if there is a statistical model appropriate for calculating a p-value, the same model can produce a corresponding confidence interval. That means that confidence intervals can be used not just to describe individual group distributions, but to describe the differences between groups.

For t-tests, the relationship between the standard error, p-value, and confidence interval for the difference between means is so close that it can seem mathematically trivial to argue for reporting one instead of the other¹⁷. If the mean and standard error are reported, then the 95% confidence interval can be calculated (mean \pm 1.96 times the standard error for large samples). If the 95% confidence interval doesn't overlap the null-hypothesis, the null hypothesis can be rejected at $p < 0.05$. However, the close mathematical relationship doesn't negate the practical difference in interpretation when one or the other statistic is used.

In the mitochondria example (Figure 1), the effect of the treatment can be reported as:

- 1) Relative to disease model (n=30), mitochondria number recovered by...
(if result A) 6.8% \pm 1.4% (SE, n = 100, $p < 0.042$)
(if result B) 56.2% \pm 22.4% (n = 10, $p = 0.045$)
(if result C) 92.7% \pm 2.5% (n = 20, $p < 0.001$).

or

- 2) Relative to untreated mutant (n = 30), mitochondria number recovered by...
(if result A) 0.3% to 13.4% (CI95, n = 100)

(if result B) 5.4% to 107.0% (CI95, n=10)
(if result C) 84.9% to 100.5% (CI95, n=30).

To perform a conservative evaluation of the mitochondria results, the reader needs to figure out the smallest likely effect size for the treatment. This information can be pulled from version 1 if the reader does some math with means and standard error. However, the estimate of the smallest likely effect size is explicit in version two. It is the lower bound of the confidence interval. The critical information, that treatment is estimated to recover at least 84% of the lost mitochondria number (or 0.3% or 5.4% for result A and B), is easy to find, easy to interpret, and easy to remember.

Confidence intervals are limited by some of the same assumptions as p-values¹⁸ and there have been arguments for throwing out both in favor of rigorous reporting of effect sizes and experimental design¹⁹. However, NHST for no-effect became ubiquitous because there is a genuine niche for a default statistical analysis that every cell biologist can calculate and interpret. Replacing p-values with confidence intervals means that data interpretation will start with a clear statement of both effect size and uncertainty about that effect size.

Imagine again the dial that increases sample size in all publications except, this time, the publications base their claims on confidence intervals. As sample size increases towards infinity, the intervals shrink, and the bounds converge towards a single point value that is the actual value of the population. When we ignore the zero-effect hypothesis and study effect sizes, more data translates into more understanding.

What happens to cell biology if we stop testing for “no-effect”?

Debate over the merits of p-values and confidence constitutes a literature unto itself and cannot be reasonably covered here^{28 11,29,30 31,32 33,34 35} and the specific problem of testing for no-effect was more elegantly explained in “The Earth Is Round ($p < .05$)”¹¹. The urgency of rehashing this debate for cell biology arises from four issues. 1) NHST for no-effect is not being used as a first pass screen, but as a conclusion generator. 2) The practice is now so universal, that it is often thought of as the sum of what statistics has to offer. 3) Evolution shapes cellular interactions in degrees of specificity. A distinction between strong and weak effects must be central to the analysis of cell biology. 4) Automation of experiments and analysis means that the worst-case hypothetical pitfalls of testing for no-effect are now a daily reality.

If we stop reporting tests for no-effect, it is likely that only a small subset of our experiments will still fit within the framework of NHST. These are the cases where the system has already been well characterized. Prior to these experiments, effect size criteria can be proposed that would delineate between competing explanations (see Supplementary Text). For the rest of our experiments, the appropriate framework for quantification is the characterization of an effect size, not the testing of a hypothesis.

Accepting that NHST should be rare doesn't mean studies can't be hypothesis driven. Whether hypothesis driven or question driven, the claims of most studies are a qualitative synthesis of the results from multiple experiments and the previous literature. The

important point is that we can't let the pressure for quantitative answers and hypothesis driven science impose the wrong quantitative framework on individual experiments.

In effect-size-centric cell biology, the gold standard for showing an important result would be to show a reliable effect size that distinguishes between plausible models of the system. The criteria of "biologically meaningful effect size" is a much higher bar than "statistically significant". Under this criterion, many fewer studies can be expected to report important experimental effects. This aspect of increased statistical rigor does not necessarily mean fewer papers will be published. An unbiased literature requires publishing both "positive" and "negative" results.

Focusing our analysis on effect size does mean that we will have to accept the reality that most experimental results are ambiguous and incremental. The implicit and, sometimes, explicit interpretation of p-values is that the result of every experiment is either "effect" or "no-effect". When we take confidence intervals seriously, we will often have to conclude that we don't have enough data to understand what is going on.

Arguing that we should produce a large online literature filled with ambiguous and negligible effect sizes is not the most appealing pitch for changing the way cell biology quantifies data. What we could gain is a literature in which biological claims reflect meaningful quantification, a literature from which we can judge the replicability of experiments, and a literature from which we can build better models of how cells work.

CODE AVAILABILITY

Matlab (Mathworks) code that can be used to experiment with different types of distributions and confidence intervals is available at <https://github.com/MorganLabShare/betterThanChance>.

APPENDIX

Calculating confidence intervals.

There are a variety of methods for calculating confidence intervals and many of these are built into common statistical software packages. The goal when choosing a method is to find one for which the actual coverage is close to the nominal coverage. If you calculate a 95% confidence interval for the mean of a distribution, the nominal coverage is 95%. The claim the calculation is making is that, if the same calculation was repeated many times for similar datasets, the calculated interval would contain the true mean 95% of the time. The extent to which this claim is true, the actual coverage of your interval, depends on how well the assumptions of the calculation fit the data.

When calculating a confidence interval to compare two groups, the model assumptions to consider are roughly the same as when calculating a p-value: Are the distributions normal? Are the sample sizes the same? Are the sample sizes large enough for a given model? Are the variances the same? Are the distributions skewed or asymmetric? As in calculating p-values, non-parametric resampling techniques can be used that make very few assumptions

about the distribution of the data^{18,20-25}. For instance, generating a confidence interval with bootstrap resampling is a common approach. For a default statistic for cell biology though, the most robust and practical approach is to start with the same statistical model we are used to using for t-tests and then to adjust as required.

The simplest way to generate a confidence interval for the difference in means between two groups is to pool the standard errors (pooled SE = $\sqrt{SE1^2 + SE2^2}$). The 95% confidence interval is then the difference between the two groups plus and minus the pooled standard error multiplied by 1.96. This method is convenient when calculating a back of the envelope confidence interval from published standard errors, but it assumes that sample sizes are large and sample sizes and variances are equal between the groups.

The Welch-Scatterhwaite confidence interval was designed to use the t distribution to calculate confidence interval when the variances of two groups are different²⁶. Miao and Chiou²⁷ find it performs well when sample sizes are the same or different, when variances are the same or different, and even when distributions are not normal. They do find that its performance decreases when distributions are asymmetric and therefore recommend a pretest for symmetry and log transformation of asymmetric data. With the caveat of detecting and correcting for asymmetric distributions, the Welch-Scatterhwaite confidence interval is then a single calculation that could reliably replace most of the p-values in the cell biology literature.

The Welch-Scatterhwaite confidence interval is more complicated to calculate than the pooled variance interval²⁷, but it is an option in most statistics software packages. For example in Matlab 2023a the WS interval can be obtained by the expression: [noThanks1 noThanks2 confidenceInterval] = ttest2(group1, group2, "Alpha", 0.05, "vartype", "unequal"). To experiment with how different kinds of confidence intervals interact with different kinds of data, Matlab code is available for download (<https://github.com/MorganLabShare/betterThanChance>).

Calculating the Welsh-Scatterhwaite confidence interval for the difference between two groups

1. Calculate the combined standard error (sp) using the standard deviation (std1, std2) and sample size (n1,n2) for two groups: $w1 = \frac{std1^2}{n1}, w2 = \frac{std2^2}{n2}, sp = \sqrt{w1 + w2}$
2. Calculate the degrees of freedom (df): $df = (w1 + w2)^2 / (\frac{w1^2}{n1-1} + \frac{w2^2}{n2-1})$
3. Look up the t-score (t) for the desired alpha using the t-distribution with df degrees of freedom. For a 95% confidence interval, alpha = 0.05: $t = tDistribution([1 - \frac{alpha}{2}], df)$
4. Calculate the confidence interval as the difference between means (m1,m2) plus and minus the combined standard error (sp) scaled by the t-score (t): $CI = (m1 - m2) \pm t * sp$

ACKNOWLEDGEMENTS

Thanks to Hrvoje Šikić, Tim Holy, Phil Williams, Daniel Kerschensteiner, and Julie Hodges for reading the manuscript and providing feedback. This work was supported by an unrestricted grant to the Department of Ophthalmology and Visual Sciences from Research to Prevent Blindness, by a Research to Prevent Blindness Career Development Award, and by the NIH (EY029313).

REFERENCES

1. Calin-Jageman, R.J. (2022). Better Inference in Neuroscience: Test Less, Estimate More. *J. Neurosci.* *42*, 8427–8431.
2. Szucs, D., and Ioannidis, J.P.A. (2017). When Null Hypothesis Significance Testing Is Unsuitable for Research: A Reassessment. *Front. Hum. Neurosci.* *11*, 390.
3. Rozeboom, W.W. (1960). The fallacy of the null-hypothesis significance test. *Psychol. Bull.* *57*, 416–428.
4. Goodman, S.N. (1993). p values, hypothesis tests, and likelihood: implications for epidemiology of a neglected historical debate. *Am. J. Epidemiol.* *137*, 485–496; discussion 497–501.
5. Meehl, P.E. (1967). Theory-testing in psychology and physics: A methodological paradox. *Philos. Sci.* *34*, 103–115.
6. Berkson, J. (1938). Some Difficulties of Interpretation Encountered in the Application of the Chi-Square Test. *J. Am. Stat. Assoc.* *33*, 526–536.
7. Hogben (1957). *Statistical Theory: The Relationship of Probability, Credibility and Error : an Examination of the Contemporary Crisis in Statistical Theory from a Behaviourist Viewpoint* (Norton).
8. Bakan, D. (1966). The test of significance in psychological research. *Psychol. Bull.* *66*, 423–437.
9. Sterling, T.D. (1959). Publication Decisions and their Possible Effects on Inferences Drawn from Tests of Significance—or Vice Versa. *J. Am. Stat. Assoc.* *54*, 30–34.
10. Gigerenzer, G. (2004). Mindless statistics. *J. Socio Econ.* *33*, 587–606.
11. Cohen, J. (1994). The earth is round ($p < 05$). *Am. Psychol.* *49*, 997–1003.
12. McShane, B.B., Gal, D., Gelman, A., Robert, C., and Tackett, J.L. (2019). Abandon Statistical Significance. *Am. Stat.* *73*, 235–245.
13. Mlodinow, L., Pratt, S., and Gildan Media, L.L.C. *The Drunkard's Walk: How Randomness Rules Our Lives*.
14. Neyman, J., and Pearson, E.S. (1933). On the problems of the most efficient tests of statistical hypotheses. *Philosophical Transactions of the Royal Society of London* *231A*, 289–338.
15. Thompson, B. (2014). The Use of Statistical Significance Tests in Research. *J. Exp. Educ.* *61*, 361–377.

16. Neyman, J. (1937). Outline of a theory of statistical estimation based on the classical theory of probability. *Philos. Trans. R. Soc. Lond.* 236, 333–380.
17. Krantz, D.H. (1999). The Null Hypothesis Testing Controversy in Psychology. *J. Am. Stat. Assoc.* 94, 1372–1381.
18. Fieberg, J.R., Vitense, K., and Johnson, D.H. (2020). Resampling-based methods for biologists. *PeerJ* 8, e9089.
19. Trafimow, D., and Marks, M. (2015). Editorial. *Basic Appl. Soc. Psych.* 37, 1–2.
20. Efron, B. (1979). Bootstrap Methods: Another Look at the Jackknife. *aos* 7, 1–26.
21. Jung, K., Lee, J., Gupta, V., and Cho, G. (2019). Comparison of Bootstrap Confidence Interval Methods for GSCA Using a Monte Carlo Simulation. *Front. Psychol.* 10, 2215.
22. Shi, S.G. (1992). Accurate and efficient double-bootstrap confidence limit method. *Comput. Stat. Data Anal.* 13, 21–32.
23. Letson, D., and McCullough, B.D. (1998). Better Confidence Intervals: The Double Bootstrap with No Pivot. *Am. J. Agric. Econ.* 80, 552–559.
24. Puth, M.-T., Neuhäuser, M., and Ruxton, G.D. (2015). On the variety of methods for calculating confidence intervals by bootstrapping. *J. Anim. Ecol.* 84, 892–897.
25. DiCiccio, T.J., Martin, M.A., and Young, G.A. (1992). Fast and accurate approximate double bootstrap confidence intervals. *Biometrika* 79, 285–295.
26. Welch, B.L. (1938). The Significance of the Difference Between Two Means when the Population Variances are Unequal. *Biometrika* 29, 350–362.
27. Miao, W., and Chiou, P. (2008). Confidence intervals for the difference between two means. *Comput. Stat. Data Anal.* 52, 2238–2248.
28. Morrison, D.E.H.R.E. ed. (1970). *The significance test controversy* (Aldine).
29. Harlow, L.L., Mulaik, S.A., and Steiger, J.H. (2013). What if there were no significance tests?
30. Fidler, F., Thomason, N., Cumming, G., Finch, S., and Leeman, J. (2004). Editors can lead researchers to confidence intervals, but can't make them think: statistical reform lessons from medicine. *Psychol. Sci.* 15, 119–126.
31. Schmidt, F.L., and Hunter, J.E. (1997). What if there were no significance tests? 37–64.
32. Amrhein, V., and Greenland, S. (2018). Remove, rather than redefine, statistical significance. *Nat Hum Behav* 2, 4.
33. Bonovas, S., and Piovani, D. (2023). On p-Values and Statistical Significance. *J. Clin. Med. Res.* 12. 10.3390/jcm12030900.
34. Wasserstein, R.L., and Lazar, N.A. (2016). The ASA Statement on p-Values: Context, Process, and Purpose. *Am. Stat.* 70, 129–133.
35. Held, L., and Ott, M. (2018). On P-Values and Bayes Factors. 10.1146/annurev-statistics-031017-100307.

36. Collaboration, O.S. (2015). Estimating the reproducibility of psychological science. *Science* 349, aac4716.
37. Van Noorden, R. (2023). Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed? Nature Publishing Group UK. 10.1038/d41586-023-02299-w.
38. Errington, T.M., Mathur, M., Soderberg, C.K., Denis, A., Perfito, N., Iorns, E., and Nosek, B.A. (2021). Investigating the replicability of preclinical cancer biology. *Elife* 10. 10.7554/eLife.71601.
39. Ioannidis, J.P.A. (2005). Contradicted and initially stronger effects in highly cited clinical research. *JAMA* 294, 218–228.